The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 08, 2018

Filed:

Aug. 24, 2010
Applicants:

Ann M. Leen, Bellaire, TX (US);

Ulrike Gerdemann, Houston, TX (US);

Cliona M. Rooney, Bellaire, TX (US);

Juan Vera, Bellaire, TX (US);

John R. Wilson, New Brighton, MN (US);

Inventors:

Ann M. Leen, Bellaire, TX (US);

Ulrike Gerdemann, Houston, TX (US);

Cliona M. Rooney, Bellaire, TX (US);

Juan Vera, Bellaire, TX (US);

John R. Wilson, New Brighton, MN (US);

Assignees:

Baylor College of Medicine, Houston, TX (US);

Wilson Wolf Manufacturing, New Brighton, MN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); C12N 5/00 (2006.01); C12N 5/02 (2006.01); C12N 5/0783 (2010.01); A61K 39/12 (2006.01); A61K 39/155 (2006.01); A61K 39/245 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0638 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/155 (2013.01); A61K 39/245 (2013.01); C12N 5/0636 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/54 (2013.01); A61K 2039/572 (2013.01); C12N 2501/23 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2312 (2013.01); C12N 2501/2315 (2013.01); C12N 2502/11 (2013.01);
Abstract

The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.


Find Patent Forward Citations

Loading…